Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
SAN RAMON, Calif., Sept. 20, 2016 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Sachs Associates 16th Annual Biotech in Europe Forum. The presentation will take place on Wednesday, September 28, 2016 at 10:15 a.m. local time at the Congress Center Basel in Basel, Switzerland.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. Galena’s pipeline consists of multiple mid-to-late-stage clinical assets led by its hematology asset, GALE-401, and novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (925) 498-7709 [email protected]
